54,783 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 54,783 shares of the company's stock, valued at approximately $761,000. Raymond James Financial Inc. owned about 0.11% of Tyra Biosciences at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new position in Tyra Biosciences during the 4th quarter valued at $404,000. Russell Investments Group Ltd. boosted its holdings in Tyra Biosciences by 130,587.5% in the fourth quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company's stock worth $145,000 after purchasing an additional 10,447 shares during the period. Wells Fargo & Company MN boosted its holdings in Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after purchasing an additional 3,236 shares during the period. Wellington Management Group LLP boosted its holdings in Tyra Biosciences by 4.4% in the fourth quarter. Wellington Management Group LLP now owns 94,859 shares of the company's stock worth $1,319,000 after purchasing an additional 4,034 shares during the period. Finally, Pictet Asset Management Holding SA acquired a new position in Tyra Biosciences in the fourth quarter worth $4,921,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Stock Up 7.7%

TYRA stock traded up $0.78 during mid-day trading on Monday, reaching $10.87. The company had a trading volume of 15,237 shares, compared to its average volume of 259,106. The stock has a market capitalization of $576.82 million, a P/E ratio of -6.71 and a beta of 1.17. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $29.60. The stock's 50-day simple moving average is $9.64 and its two-hundred day simple moving average is $13.10.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wedbush reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.